Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) will host a conference call on May 16, 2022, at 4:30 p.m. ET to discuss its Q1 2022 financial results and update on its business and pipeline. The conference call is accessible at 1-877-704-4453 (domestic) or 1-201-389-0920 (international) using conference ID 13729221. Additionally, an audio webcast will be available on its website, which will be archived for 30 days. Spero focuses on developing treatments for complicated bacterial infections, with the FDA reviewing its New Drug Application for tebipenem HBr.

Positive

• A New Drug Application for tebipenem HBr is under FDA review.
• Spero is developing several innovative therapies for serious bacterial infections, including SPR720 for a rare pulmonary disease and SPR206 for multidrug resistant infections.

Negative

• Tebipenem HBr is still not FDA-approved, indicating reliance on future approval for revenue.

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13729221. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multidrug resistant bacterial infections and rare diseases.

• A New Drug Application for tebipenem pivoxil hydrobromide oral tablets (tebipenem HBr) is currently being reviewed by the FDA; tebipenem HBr is currently not FDA-approved.
  
  
• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options.
  
  
• Spero Therapeutics is also developing SPR720 as a novel candidate oral therapy for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  
  
• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multidrug resistant Gram-negative infections in the hospital setting.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations
Tjenkins@sperotherapeutics.com
(617) 798-4039

Media Contact:
Jacqueline Pomfret Kirby
Vice President, Corporate Affairs
Jkirby@sperotherapeutics.com
(617) 798-4074

FAQ

What is the date of Spero Therapeutics' Q1 2022 earnings call?

Spero Therapeutics' Q1 2022 earnings call is scheduled for May 16, 2022.

How can I access the Spero Therapeutics conference call?

You can access the conference call by dialing 1-877-704-4453 for domestic calls or 1-201-389-0920 for international calls with conference ID 13729221.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing novel treatments for bacterial infections, including multidrug resistant and rare diseases.

Is tebipenem HBr approved by the FDA?

No, tebipenem HBr is currently not FDA-approved but is under review.

What are the main therapies being developed by Spero Therapeutics?

Spero is developing tebipenem HBr for urinary tract infections, SPR720 for a pulmonary disease, and SPR206 for multidrug resistant infections.